Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Khaled Moumneh

Ophthalmology Deland, FL Doctor of Osteopathy

NPI 1831775469 CMS profile 11420355

1592 S Sr 15A, Deland, FL 32720

Open in the dashboard

General payments

$5,460

66 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khaled Moumneh of Deland, FL is reported in the CMS Open Payments database as having received $5,460 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $769 15
2024 General $2,158 24
2023 General $2,265 22
2022 General $269 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khaled Moumneh
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Khaled Moumneh were reported at $769. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Khaled Moumneh Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $269 $266 $100–$678 $149
2023 $2,265 $308 $117–$745 $160
2024 $2,158 $340 $127–$846 $164
2025 $769 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Bausch & Lomb Americas Inc. $3,501 31 payments
  2. Alcon Vision LLC $477 10 payments
  3. AbbVie, Inc. $468 8 payments
  4. Johnson & Johnson Surgical Vision, Inc. $429 3 payments
  5. Amgen Inc. $161 3 payments
  6. Mallinckrodt Hospital Products Inc. $121 1 payment
  7. Glaukos Corporation $105 2 payments
  8. Harrow Eye, LLC $95 4 payments
  9. Dompe US, Inc. $33 1 payment
  10. Rayner Intraocular Lenses Limited $27 1 payment
  11. Other $43 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,846 57 payments
  2. Travel and Lodging $2,614 9 payments
Products named General payments · program years 2022–2025
  1. STELLARIS ELITE $3,476 30 payments
  2. enVista MX60 IOL $3,476 30 payments
  3. Trulign IOL $3,476 30 payments
  4. Crystalens Accommodating IOL (AT-52AO) $3,476 30 payments
  5. Akreos AO IOL $1,805 17 payments
  6. XEN GLAUCOMA TREATMENT SYSTEM $294 3 payments
  7. LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE) $262 1 payment
  8. LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE $262 1 payment
  9. MEIBOMIAN GLAND EVALUATOR $262 1 payment
  10. LIPIVIEW OCULAR SURFACE INTERFEROMETER $262 1 payment
  11. Other $1,514 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record